Infectious Diseases News and Research

RSS

Scientists discover FAIM molecule as potential biomarker for bone marrow cancer

Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow.

14 Dec 2012

NovaDigm announces data from NDV-3 vaccine Phase 1 study on Candida and Staph infections

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the publication of data from its first-in-human Phase 1 study of its NDV-3 vaccine program in the journal Vaccine.

13 Dec 2012

Fatal imbalance between global disease burden and drug development

Despite important progress in research and development (R&D) for global health over the past decade, only a small fraction of new medicines developed between 2000 and 2011 were for the treatment of neglected diseases, highlighting the 'fatal imbalance' between global disease burden and drug development for some of the world most devastating illnesses, said Doctors Without Borders/M-decins Sans Fronti-res (MSF) and the Drugs for Neglected Diseases initiative (DNDi), in an analysis to be presented today at an international conference aimed at spurring medical innovations for these diseases.

13 Dec 2012

TU Darmstadt’s biosensor can diagnose African sleeping sickness before it breaks out

African sleeping sickness is an infectious disease that is widespread south of the Sahara Desert. Although the around sixty million people residing in tropical Africa run the risk of becoming infected with the disease every day, only around four million of them are monitored for the disease by disease-control authorities.

13 Dec 2012

New way to effectively make designer drugs that hit collections of protein targets simultaneously

An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.

13 Dec 2012

Medivir commences cohort 2 simeprevir and sofosbuvir phase II combination trial in HCV GT1

Medivir AB, announced today the initiation of cohort 2 in the interferon-free phase II trial combining simeprevir with sofosbuvir (GS7977) based on a safety and efficacy planned interim analysis of cohort 1 including prior null responder HCV genotype 1 infected patients without advanced hepatic fibrosis.

13 Dec 2012

Heartbeat Experts announces increased revenue and expanded clients in emerging markets

Heartbeat Experts, the global leader in stakeholder management solutions for the life sciences industry, announced today increased revenue and expanded clients across Brazil, Russia, China, India and Korea. Heartbeat Experts' reported combined revenue from these markets grew 50% in the third quarter of 2012.

13 Dec 2012

Study investigates different approaches to eradicate mosquito-borne diseases

A special issue of Pathogens and Global Health, published by Maney Publishing, investigates different approaches to eradicate mosquito-borne diseases. Mosquitoes can transmit a number of pathogenic diseases including dengue fever, yellow fever, and malaria.

13 Dec 2012

Scientists determine specific genetic switches that sync liver activity to the circadian cycle

When it's dark, and we start to fall asleep, most of us think we're tired because our bodies need rest. Yet circadian rhythms affect our bodies not just on a global scale, but at the level of individual organs, and even genes.

12 Dec 2012

Adversity in childhood can shape long-term health outcomes

Noting the "16 Days of Activism Against Gender Violence," Neil Boothby, U.S. government special adviser and senior coordinator to the USAID administrator on children in adversity, writes in USAID's "IMPACTblog," "The science is clear -- childhood experiences shape adult outcomes, including long-term health, cognitive development, academic achievement, and one's ability to be gainfully and safely employed."

12 Dec 2012

AstraZeneca, Case Western Reserve initiate AZD5847 Phase 2a trial in TB

Case Western Reserve University School of Medicine and AstraZeneca, a global biopharmaceutical company, today announced the first patient enrolled in a Phase 2a trial to assess the effectiveness of AZD5847, a new test drug for patients with tuberculosis (TB), including patients with HIV co-infection.

12 Dec 2012

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.

12 Dec 2012

Clinical trial to examine AstraZeneca experimental drug against pulmonary tuberculosis

A clinical trial will examine an investigational drug's early bacteria-killing activity in patients newly diagnosed with drug-sensitive pulmonary tuberculosis.

12 Dec 2012

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Durata Therapeutics, Inc. today announced preliminary, top-line results for its DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response") Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including MRSA (methicillin resistant Staphylococcus aureus).

11 Dec 2012

Roundup: NH hospital at center of hepatitis outbreak details fixes; Report finds racial gap in Colo. dental coverage; Health cuts part of Conn. budget plan

Though Exeter Hospital has fixed problems discovered after a hepatitis C outbreak last spring, federal officials say the hospital initially failed to conduct an adequate investigation. The Centers for Medicare and Medicaid Services said last week it no longer plans to terminate the hospital's Medicare funding now that multiple issues raised by inspectors have been addressed.

11 Dec 2012

Age, functional status predict return to acute care for burn patients

Older age and lower functional status at admission increase a patient’s likelihood of being transferred from a burn rehabilitation unit back to acute care, show study findings.

11 Dec 2012

Telestroke networks benefit hospital bank balances

Telestroke networks can increase the number of patients successfully discharged home while saving money for all hospitals involved, show US study results.

11 Dec 2012

Chest-compression-only CPR ‘should be standard’ for bystander resuscitation

Cardiopulmonary resuscitation with chest compressions only seems to be the most effective form of resuscitation when delivered by lay bystanders along with public-access automated external defibrillation, research suggests.

11 Dec 2012

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.

11 Dec 2012

Infectious Diseases News and Research

Scientists discover FAIM molecule as potential biomarker for bone marrow cancer

NovaDigm announces data from NDV-3 vaccine Phase 1 study on Candida and Staph infections

Fatal imbalance between global disease burden and drug development

TU Darmstadt’s biosensor can diagnose African sleeping sickness before it breaks out

New way to effectively make designer drugs that hit collections of protein targets simultaneously

Medivir commences cohort 2 simeprevir and sofosbuvir phase II combination trial in HCV GT1

Heartbeat Experts announces increased revenue and expanded clients in emerging markets

Study investigates different approaches to eradicate mosquito-borne diseases

Scientists determine specific genetic switches that sync liver activity to the circadian cycle

Adversity in childhood can shape long-term health outcomes

AstraZeneca, Case Western Reserve initiate AZD5847 Phase 2a trial in TB

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

Clinical trial to examine AstraZeneca experimental drug against pulmonary tuberculosis

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Roundup: NH hospital at center of hepatitis outbreak details fixes; Report finds racial gap in Colo. dental coverage; Health cuts part of Conn. budget plan

Age, functional status predict return to acute care for burn patients

Telestroke networks benefit hospital bank balances

Chest-compression-only CPR ‘should be standard’ for bystander resuscitation

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Janssen announces U.S. prescribing information update for EDURANT tablets

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News